Bell Rock Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bell Rock Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100	Closed	-$1K	–	338
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	377
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	359
2019 Q2	$1K	Hold	100	–	–	﹤0.01%	367
2019 Q1	$1K	Hold	100	–	–	﹤0.01%	408
2018 Q4	$2K	Hold	100	–	–	﹤0.01%	397
2018 Q3	$2K	Hold	100	–	–	﹤0.01%	408
2018 Q2	$3K	Hold	100	–	–	﹤0.01%	416
2018 Q1	$3K	Hold	100	–	–	﹤0.01%	412
2017 Q4	$4K	Hold	100	–	–	﹤0.01%	392
2017 Q3	$3K	Hold	100	–	–	﹤0.01%	380
2017 Q2	$3K	Hold	100	–	–	﹤0.01%	391
2017 Q1	$2K	Hold	100	–	–	﹤0.01%	344
2016 Q4	$2K	Buy	+100	New	+$1.68K	﹤0.01%	341

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bell Rock Capital's RVNC Position: Q1 2020 in Review

Bell Rock Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2020, closing a stake of 100 shares — an estimated $1K sold.

Bell Rock Capital first reported a position in RVNC in Q4 2016 and held it in 13 quarters. The position peaked at $4K in Q4 2017. 130 funds tracked by Wall St. Rank hold RVNC as of Q1 2020.

Bell Rock Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Bell Rock Capital sold 100 Revance Therapeutics, Inc. shares in Q1 2020, an estimated $1K.
Bell Rock Capital first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 13 quarters.
Bell Rock Capital's Revance Therapeutics, Inc. position peaked at $4K in Q4 2017.
130 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2020.

Based on Bell Rock Capital's 13F filing for Q1 2020, filed 7 May 2020.